TNFRSF18 and neoplasm: To test this hypothesis, we dosed tumor-bearing animals with anti-TIGIT:mIgG2a antibodies as well as anti-GITR:mIgG2a (clone: DTA1) or anti-PD-1:mIgG1* as positive or negative controls for intratumoral Treg depletion, respectively.